Global Infectious Disease Diagnostics Market Insights Forecasts to 2032.
- The Global Infectious Disease Diagnostics Market Size was valued at USD 22.47 Billion in 2022.
- The Market is Growing at a CAGR of 5.4% from 2022 to 2032
- The Worldwide Infectious Disease Diagnostics Market Size is expected to reach USD 38.02 Billion by 2032.
- Asia-Pacific is expected to Grow higher during the forecast period.
Get more details on this report -
The Global Infectious Disease Diagnostics Market Size is expected to reach USD 38.02 Billion by 2032, at a CAGR of 5.4% during the forecast period 2022 to 2032.
Infectious Disease Diagnostics play a crucial role in identifying and managing infections caused by various pathogens, including bacteria, viruses, fungi, and parasites. These diagnostics encompass a diverse range of techniques aimed at detecting and characterizing infectious agents within patient samples. Rapid advancements in molecular biology have led to the development of nucleic acid-based tests like PCR and next-generation sequencing, enabling accurate and rapid identification of pathogens and their genetic traits. Serological assays measure specific antibodies to determine exposure and immunity. Additionally, immunological methods such as antigen detection assays and culture-based techniques aid in pinpointing infectious agents. These diagnostics contribute significantly to early detection, proper treatment, and effective containment of infectious diseases, ultimately improving patient outcomes and public health responses.
This research report categorizes the market for infectious disease diagnostics market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the infectious disease diagnostics market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the infectious disease diagnostics market.
Global Infectious Disease Diagnostics Market Report Coverage
|Market Size in 2022:||USD 22.47 Billion|
|Forecast Period 2022-2032 CAGR:||5.4%|
|2032 Value Projection:||USD 38.02 Billion|
|Historical Data for:||2018-2021|
|No. of Pages:||200|
|Tables, Charts & Figures:||120|
|Segments covered:||By Product, By Technology, By Application, By End-use, By Region and COVID-19 Impact Analysis.|
|Companies Covered:||Abbott Laboratories, BioMerieus SA, Becton, Dickinson and Company, Danaher Corporation, Bio-Rad Laboratories, F Hoffman-La Roche, Hologic Inc., Qiagen Inc., Siemens Healthineers, Thermo Fisher Scientific Inc. and other key venders.|
|Pitfalls & Challenges:||COVID-19 Empact, Challenge, Future, Growth, & Analysis|
Get more details on this report -
The infectious disease diagnostics market is propelled by a confluence of factors that collectively shape its growth trajectory, the persistent global threat of emerging and re-emerging infectious diseases necessitates advanced diagnostic tools for timely identification and management. Additionally, the increasing incidence of infections, fueled by factors such as population growth, urbanization, and travel, underscores the demand for accurate and rapid diagnostics. The growing awareness among healthcare professionals and the general public about the importance of early detection further drives market expansion. Moreover, technological advancements in molecular and immunological techniques play a pivotal role. Innovations like PCR, next-generation sequencing, and point-of-care testing enhance diagnostic accuracy and speed, thereby stimulating market adoption. Furthermore, the imperative to combat antimicrobial resistance amplifies the need for precise diagnostics, guiding appropriate treatment strategies. Healthcare infrastructure development, particularly in developing regions, presents a substantial opportunity for market growth as access to diagnostic facilities improves. Government initiatives, funding, and collaborations for infectious disease control and prevention foster a supportive ecosystem. The COVID-19 pandemic, while devastating, accelerated research and investment in diagnostics, leading to a wider application of these technologies beyond the pandemic. Overall, the interplay of epidemiological trends, technological innovation, public health priorities, and global collaborations collectively propel the infectious disease diagnostics market forward.
Challenges in the infectious disease diagnostics market include limited access to diagnostic facilities in certain regions, resource constraints affecting affordability, and complexities in developing tests for diverse pathogens. Regulatory hurdles, varying disease patterns, and evolving pathogen strains add complexity. Additionally, diagnostic accuracy, sensitivity, and specificity can impact reliability. Rapid technological advancements may lead to adoption challenges and the need for continuous training. Competitive market dynamics and reimbursement issues further constrain growth.
- In 2022, the reagents, kits & consumables segment accounted for around 42.8% market share
On the basis of the product, the global infectious disease diagnostics market is segmented into instruments, reagents, kits & consumables, and services. The reagents, kits, and consumables segment has emerged as the dominant force in the infectious disease diagnostics market due to its essential role in facilitating diagnostic procedures. These components form the backbone of diagnostic tests, enabling accurate pathogen detection and characterization. With consistent demand for diagnostic assays, this segment has experienced robust growth. The reliance on standardized reagents, user-friendly kits, and reliable consumables underscores their critical importance in ensuring consistent and reproducible results. This segment's significant market share is a testament to its indispensable role in supporting a wide array of infectious disease diagnostic platforms and technologies.
- The immunodiagnostics segment held the largest market with more than 38.5% revenue share in 2022
Based on the technology, the global infectious disease diagnostics market is segmented into clinical microbiology, polymerase chain reaction, in situ hybridization, isothermal nucleic acid amplification technology, immunodiagnostics, and others. The immunodiagnostics segment has captured the largest market share in infectious disease diagnostics due to its pivotal role in detecting infections. Utilizing the immune response, immunodiagnostics offer a diverse range of tests, including serological assays and antigen detection methods, enabling accurate identification of various pathogens. This segment's widespread adoption is driven by its high sensitivity, specificity, and versatility, making it a cornerstone in infectious disease detection. Its prominence reflects the crucial contribution of immunodiagnostics to effective disease management and public health efforts.
- Respiratory diseases segment is expected to grow at the fastest CAGR of around 5.7% during the forecast period
Based on the application, the global infectious disease diagnostics market is segmented into COVID-19, gastrointestinal tract infections, respiratory diseases, sexually transmitted infections, tuberculosis, hospital-acquired infection, mosquito-borne diseases, and others. The respiratory diseases segment is poised for rapid growth during the forecast period due to the increasing prevalence of respiratory infections, coupled with the ongoing COVID-19 pandemic, has heightened the demand for accurate and timely diagnostic solutions. Early detection of respiratory pathogens is crucial for effective disease management and containment. Advances in molecular and point-of-care testing have enhanced the speed and accuracy of respiratory disease diagnostics. Additionally, heightened awareness and healthcare infrastructure improvements in this area further contribute to the segment's projected fast-paced expansion in the infectious disease diagnostics market.
- The hospitals segment held the largest market over the forecast period
Based on the end-use, the global Infectious disease diagnostics market is segmented into hospitals, clinics, diagnostics laboratories, research institutes, and others. The hospitals segment has dominated the infectious disease diagnostics market over the forecast period due to its pivotal role as a primary point of patient care and disease management. Hospitals offer comprehensive diagnostic services, equipped with advanced technologies and expert medical professionals, making them central hubs for infectious disease testing. The constant influx of patients, combined with the need for timely and accurate diagnoses, has driven the segment's prominence in the market.
Regional Segment Analysis of the Infectious Disease Diagnostics Market
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Rest of APAC)
- South America (Brazil and the Rest of South America)
- The Middle East and Africa (UAE, South Africa, Rest of MEA)
North America dominated the market with more than 45.5% revenue share in 2022.
Get more details on this report -
Based on region, North America commands the infectious disease diagnostics market due to its robust healthcare infrastructure, advanced research capabilities, and high healthcare expenditure. The region's early adoption of innovative diagnostic technologies, coupled with a proactive approach to disease surveillance and control, has solidified its dominance. Furthermore, strategic partnerships between industry players and research institutions have driven market growth.
Asia-Pacific is poised for substantial growth in the infectious disease diagnostics market during the forecast period due to factors such as rising population, increasing healthcare investments, and improving healthcare infrastructure. The region's susceptibility to infectious diseases, coupled with the growing demand for rapid and accurate diagnostics, is driving market expansion.
- In July 2022, F. Hoffmann-La Roche Ltd has introduced a novel hepatitis C dual antigen and antibody diagnostic test. The new Elecsys HCV Duo immunoassay test is one of the first commercially available immunoassay tests that can determine the hepatitis C virus strain from a single human plasma or blood sample.
- In April 2022, Bio-Rad Laboratories demonstrated their whole portfolio of infectious disease testing reagents, equipment, and quality controls to expedite test operations and give high-quality results.
The report offers the appropriate analysis of the key organizations/companies involved within the global infectious disease diagnostics market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Companies:
- Abbott Laboratories
- BioMerieus SA
- Becton, Dickinson and Company
- Danaher Corporation
- Bio-Rad Laboratories
- F Hoffman-La Roche
- Hologic Inc.
- Qiagen Inc.
- Siemens Healthineers
- Thermo Fisher Scientific Inc.
Key Target Audience
- Market Players
- Government Authorities
- Consulting and Research Firm
- Venture Capitalists
- Value-Added Resellers (VARs)
This study forecasts revenue at global, regional, and country levels from 2019 to 2032. Spherical Insights has segmented the global infectious disease diagnostics market based on the below-mentioned segments:
Infectious Disease Diagnostics Market, By Product
- Reagents, kits & consumables
Infectious Disease Diagnostics Market, By Technology
- Clinical Microbiology
- Polymerase chain reaction
- In Situ Hybridization
- Isothermal Nucleic Acid Amplification Technology
Infectious Disease Diagnostics Market, By Application
- Gastrointestinal Tract Infections
- Respiratory Diseases
- Sexually Transmitted Infections
- Hospital acquired infection
- Mosquito-borne diseases
Infectious Disease Diagnostics Market, By End-Use
- Diagnostics Laboratories
- Research Institutes
Infectious Disease Diagnostics Market, Regional Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Need help to buy this report?